NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Avalo Therapeutics, Inc. (AVTX) Stock Analysis

Avalo Therapeutics, Inc. (AVTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AVTX

$12.26

−$0.10 (−0.81%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AVTX with… →

AVTX Key Statistics

As of Oct 21, 2026
Trading
Open
$12.41
Previous Close
$12.36
Day's Range
12.22–13.18
52-Week Range
11.21–24.27
Volume
930.11K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.70
Valuation
Market Cap
$657.50M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.31
Financials (FY)
Revenue (FY)
$59.00K−86.62%
Net Income (FY)
−$78.26M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
53.63M
1-Year Return
−29.66%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
967.86K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AVTX closed at $12.26, −29.66% over 1 year.

Avalo Therapeutics, Inc. (AVTX) has a market capitalization of $657.50M.

In fiscal 2025, AVTX reported revenue of $59.00K.

AVTX Stock Return by Calendar Year

Avalo Therapeutics, Inc. (AVTX) 10-year return: what $10,000 became

1 year
$10,000 $7,034
−29.66%
5 years
$10,000 $19
−99.81%
10 years
$10,000 $10
−99.90%

If you had invested $10,000 in Avalo Therapeutics, Inc. (AVTX) 10 years ago, at the close on October 21, 2016, it would have been worth $10 at the close on October 21, 2026: −99.90% in total, −49.68% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−32.49%
2025+144.41%
2024−18.35%
2023−99.25%
2022−75.29%
2021−35.61%
2020−51.02%
2019+66.87%
2018+0.94%
2017+263.64%
2016 (partial year)−78.80%

As of October 21, 2026.

AVTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$59.00K−$78.26M−132,642.4%
2024$441.00K−$35.13M−7,965.8%
2023$1.92M−$31.54M−1,639.5%
2022$18.05M−$41.66M−230.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$59.00K$59.00K−$72.93M−$78.26M−132,642.4%
2024$441.00K$807.00K−$40.87M−$35.13M−7,965.8%
2023$1.92M$640.00K−$23.44M−$31.54M−1,639.5%
2022$18.05M$14.62M−$37.44M−$41.66M−230.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Avalo Therapeutics, Inc. (AVTX) is capitalised at $657.50M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 33.

Over the past 52 weeks the price has ranged from $11.21 to $24.27. AVTX last closed at $12.26 on October 21, 2026. That is −$0.10 (−0.81%) against the previous close. The latest close sits 9.37% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $59.00K. Against the prior fiscal year total of $441.00K, that is a change of −86.62%. The same year closed with a net loss of $78.26M. Earnings per share on a trailing basis come to −4.31.

Across the 4 fiscal years on file, revenue moves from $18.05M in 2022 to $59.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.7. Daily returns over the trailing 10 years annualize to a volatility of 164.9%. Over the trailing twelve months the total return is −29.66%. Measured over 10 years, that is −49.68% a year compounded.

Growth & Income

No dividend is on file for AVTX.

Across the complete calendar years on file, 2017 returned +263.64% and 2023 returned −99.25%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the total return is −32.49%.

Peer Comparison

Avalo Therapeutics, Inc. (AVTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Avalo Therapeutics, Inc. AVTX $657.50M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Avalo Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Visit website →